Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress

GlobeNewswire October 19, 2022

Plus Therapeutics to Present at the ThinkEquity Conference

GlobeNewswire October 18, 2022

Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022

GlobeNewswire October 6, 2022

Plus Therapeutics Announces Patient Webinar in Recognition of Breast Cancer Awareness Month

GlobeNewswire October 5, 2022

Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT(TM) Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine

GlobeNewswire October 4, 2022

Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas

GlobeNewswire September 22, 2022

Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022

GlobeNewswire September 12, 2022

Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 8, 2022

Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate

GlobeNewswire September 6, 2022

Plus Therapeutics Announces Summary of FDA Meeting on Company's cGMP Manufacturing Process for Lead Drug Candidate

GlobeNewswire August 29, 2022

Plus Therapeutics to Present Data from ReSPECT-GBM(TM) Clinical Trial at the European Society for Medical Oncology Congress 2022

GlobeNewswire August 23, 2022

Plus Therapeutics Awarded $17.6 Million from State of Texas

GlobeNewswire August 17, 2022

Plus Therapeutics Announces Share Repurchase Program

GlobeNewswire August 15, 2022

Plus Therapeutics Presents Positive Data from Ongoing ReSPECT(TM) Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

GlobeNewswire August 13, 2022

Plus Therapeutics to Present Data from Ongoing ReSPECT(TM) Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

GlobeNewswire July 28, 2022

Plus Therapeutics to Present at Inaugural Targeted Radiopharmaceuticals Summit

GlobeNewswire July 27, 2022

Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

GlobeNewswire July 21, 2022

Plus Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on July 21, 2022

GlobeNewswire July 13, 2022

Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic

GlobeNewswire July 12, 2022

Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial

GlobeNewswire June 22, 2022